Key result
Sulodexide therapy for 6 months did not significantly increase the achievement of normoalbuminuria or a 50% reduction in ACR compared to placebo (25.3% vs 15.4%; P=0.26).
Why the study?
Does sulodexide reduce persistent albuminuria in patients with type 2 diabetes on ACEI/ARB therapy?
RCT (n=149)
Double-blind
equal allocation
Yes
Does sulodexide reduce persistent albuminuria in patients with type 2 diabetes on ACEI/ARB therapy?
A 6-month pilot study of sulodexide in patients with type 2 diabetes and persistent albuminuria on ACEI/ARB therapy showed a non-significant trend toward improved albuminuria.
Answers are grounded in this paper and cite their sources.
Does not support adding sulodexide to ACEI/ARB for albuminuria in T2DM; larger trials needed to assess any benefit.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Heerspink et al. (2007) conducted an RCT in Type 2 diabetes and persistent albuminuria (n=149). Sulodexide vs. Placebo was evaluated on Achievement at 6 months of either return to normoalbuminuria (ACR < 20 mg/g with a decrease of at least 25%) or a decrease in ACR of at least 50% from baseline (p=0.26). Sulodexide therapy for 6 months did not significantly increase the achievement of normoalbuminuria or a 50% reduction in ACR compared to placebo (25.3% vs 15.4%; P=0.26).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: